Ethan A. Courchesne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ethan A. Courchesne has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Sampson
Oxford Vaccine Group (OVG), Department of Paediatrics, University of Oxford, Oxford, UK; Pandemic Sciences Institute (PSI), Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication - Alexandra J. Spencer
School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia
1 shared publication - Cameron Bissett
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom
1 shared publication - Claire Powers
Pandemic Sciences Institute, University of Oxford 2 , Oxford
1 shared publication - Fionn Nok Lam Ma
Oxford Vaccine Group, University of Oxford 1 Department of Paediatrics Oxford
1 shared publication - Lyn Yong
Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford; Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (1)
Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms
Seasonal booster vaccination is the primary intervention for protection from respiratory viral infections, such as influenza virus or SARS-CoV-2. However, efficacy is often limited because immune exposure to prior strains impairs development of new responses. In this study, we sought to determine how this issue could be overcome in a mouse model of heterologous immunization against WT and omicron strains of SARS-CoV-2. Intranasal booster immunization circumvented the shortcomings of intramuscular immunization, resulting in superior systemic and mucosal T and B cell immunity and better viral control following SARS-CoV-2 challenge in hamsters. Mechanistically, an intranasal omicron booster immunization bypassed deleterious immune imprinting following intramuscular ancestral strain prime, which allowed for induction of de novo lung B cell and antibody responses against the omicron strain. Cross-reactive memory T cells were also efficiently recruited into the lungs. These findings support further testing of mucosal booster vaccines against respiratory viruses, particularly as a means of simultaneously overcoming deleterious immunological imprinting and enhancing mucosal responses.
- 30 October 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (1)
Open AccessHeterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms
Seasonal booster vaccination is the primary intervention for protection from respiratory viral infections, such as influenza virus or SARS-CoV-2. However, efficacy is often limited because immune exposure to prior strains impairs development of new responses. In this study, we sought to determine how this issue could be overcome in a mouse model of heterologous immunization against WT and omicron strains of SARS-CoV-2. Intranasal booster immunization circumvented the shortcomings of intramuscular immunization, resulting in superior systemic and mucosal T and B cell immunity and better viral control following SARS-CoV-2 challenge in hamsters. Mechanistically, an intranasal omicron booster immunization bypassed deleterious immune imprinting following intramuscular ancestral strain prime, which allowed for induction of de novo lung B cell and antibody responses against the omicron strain. Cross-reactive memory T cells were also efficiently recruited into the lungs. These findings support further testing of mucosal booster vaccines against respiratory viruses, particularly as a means of simultaneously overcoming deleterious immunological imprinting and enhancing mucosal responses.